Current stock page

Catalysts

HRMY Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

HRMYHarmony Biosciences Holdings, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$33.76−$0.04 (−0.12%)

Latest quote

  • Momentum
    66
  • Value
    89
  • Quality
    77
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 23, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 73/100

Momentum 66/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 18.75%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 66/100AIQ Edge 9/10 Strong Relative Position
Beat rate
38%
3 of 8 reported periods
Average surprise
-5.7%
Across covered historical reports
Latest result
-25.7%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—$1.09$0.81-25.7%$272.05M$268.92M
Aug 4, 2026—$0.96$1.28+33.9%$250.77M$261.28M
May 7, 2026—$0.76$0.55-27.6%$220.84M$215.39M
Feb 24, 2026—$0.84$0.38-54.8%$240.33M$243.78M
Nov 4, 2025—$0.92$0.87-5.4%$240.04M$239.46M
Aug 5, 2025—$0.78$0.68-12.8%$220.16M$200.49M
May 6, 2025—$0.59$0.78+32.2%$206.05M$184.73M
Feb 25, 2025—$0.74$0.85+14.9%$183.21M$201.27M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
8
Buy
3
Hold
1
Sell
12-month analyst target
$51.50
+52.55% versus current price
Based on 12 analyst observations. Targets are estimates, not predictions.
Low target
$42.00
+24.41% vs latest price
Average target
$51.50
+52.55% vs latest price
High target
$60.00
+77.73% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 23, 2027

Next known earnings or reporting date.

EPS estimate$1.09

Current analyst expectation for the upcoming report.

Revenue estimate$281.57M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score66

Where event reaction would show up first.

AIQ score73/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
12
Average target
$51.50
Target upside
52.55%
Target range
$42.00 - $60.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
1
Negative
1
seekingalpha.com · Nov 4, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call November 4, 2026 8:30 AM ESTCompany ParticipantsBrennan Doyle - VP & Head of Investor...

zacks.com · Nov 4, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -19.00% and -0.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

zacks.com · Oct 28, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

gurufocus.com · Oct 27, 2026

Harmony Biosciences (HRMY) Gains Investor Attention with Strong Revenue Growth and Attractive Valuation

On October 27, 2026, healthcare stocks demonstrating solid year-over-year revenue growth and compelling valuations have drawn increased investor focus, with Har

gurufocus.com · Oct 19, 2026

HRMY Reiterated by Needham -- Price Target Maintained at $50.00

Harmony Biosciences Holdings Inc: Analyst Rating and GF Score Analysis On October 13, 2026, Needham reiterated its "Buy" rating for Harmony Biosciences Hldgs

Open full news and sentiment

HRMY Catalysts FAQ

What are the next catalysts for HRMY stock?

HRMY's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move HRMY stock?

Upcoming events that could move HRMY include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could HRMY's next earnings report affect the stock?

HRMY's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive HRMY stock higher?

HRMY could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt HRMY stock?

HRMY could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.